|Articles|February 10, 2023
SCOPE 2023: Beat AML Master Trial Successes
Author(s)Lisa Henderson
Len Rosenberg, head of clinical operations at Beat AML, discusses the outcome of his company's study, which was four years in the making.
Advertisement
In an interview at the 2023 SCOPE conference with ACT Editor-in-Chief, Lisa Henderson, Len Rosenberg, head of clinical operations at Beat AML, updates the public on the trial results (which he was a lead author of) and how the use of precision medicine guidelines played a role.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
Validity, Reliability, and Regulatory Considerations for Consumer Devices in Clinical Research Data Collection
2
ACT Brief: Real-Time Review Ecosystem Approach, AI Infrastructure Before Tools, and FDA Peptide Compounding Access
3
ACT Brief: ESG as Commercial Selection Factor, Real-Time Monitoring Scale Readiness, and FDA Cancer Trial Eligibility Expansion
4
FDA Finalizes Three Guidances to Broaden Cancer Clinical Trial Eligibility
5